During the Health System Executive Summit, Candy Tsourounis, PharmD, and Elise Wozniak, PharmD got candid about the barriers and financial risk surrounding this innovative therapy.
News|Articles|February 1, 2010
Formulary Digital Edition February 2010
Approaching the ideal selective estrogen receptor modulator for prevention and treatment of postmenopausal osteoporosis; Exenatide LAR: A sustained-release formulation of exenatide for the treatment of type 2 diabetes; and Agents in late-stage development for renal diseases
Advertisement
Advertisement
Related to this article
Foundational Pharmacy Strategies’ Christine Johnston on how rebate structures, pending legislation, and a stalled pipeline are reshaping — and threatening — the biosimilar market heading into 2027.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Long-acting lenacapavir plus cabotegravir kept all 46 patients with HIV virally suppressed in recent trial
2
Why biosimilars keep losing ground to brand-name rivals: A Q&A with Christine Johnston, MBA
3
Chad Hatfield, Pharm.D., on the 340B uncertainty facing health systems| HSES 2026
4
Experts say cost barriers and stigma keep eligible adults from lung cancer screening
5